SUBSCRIBE
SUBSCRIBE
News   Policy

US FDA Panel Backs Pfizer Inc. (JOBS) Osteoporosis Drug

September 9, 2008 | 
1 min read
ROCKVILLE, Md., Sept 8 (Reuters) - A Pfizer Inc drug rejected by U.S. regulators three years ago won support from an expert advisory panel on Monday for treating women with the bone-thinning disease osteoporosis.
Regulatory
Pfizer Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Insights
From Two Trials to One, Sponsors Face a Higher Standard
March 12, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Illustration of a yellow envelope on a blue background with a read warning symbol
GLP-1
Novo Hit With FDA Warning Letter for Unreported Ozempic Safety Signals
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of human hands holding a arrow pointing up, graphs and diagrams. Concept of profit, making money, business. Copy space.
Duchenne muscular dystrophy
Capricor Shares Rise as FDA Sets August Decision Date for Rejected Duchenne Therapy
March 11, 2026
 · 
2 min read
 · 
Tristan Manalac
Podcast
Prasad Out at FDA, Lawmaker Takes Action on Rare Disease Rejections and a Spate of Obesity Data
March 11, 2026
 · 
1 min read
 · 
Heather McKenzie